NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia ...

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Intellia Therapeutics, Inc. ("Intellia" or the "Company") (NASDAQ:NTLA). Such ...

NEW YORK CITY, NY / ACCESS Newswire / January 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

Intellia Therapeutics Inc (NTLA) stock saw a modest uptick, ending the day at $9.5 which represents a slight increase of $0.08 or 0.85% from the prior close of $9.42. The stock opened at $9.48 and ...

Hennion & Walsh Asset Management Inc. lifted its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 125.2 ...

NTLA stock falls more than 21% in a week after the company announced strategic priorities and key anticipated milestones for 2025. We advise prospective investors to stay on the sidelines for now.

A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization.

Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the ...

Neumora Therapeutics Inc.’s stock tumbled 81% Thursday after the clinical-stage biotech said a late-stage trial of a treatment for major depressive disorder failed to meet its main goals.

N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...

It was an extremely busy week in the biotech sector, with several companies making important presentations at the J.P. Morgan ...